Long-Term Follow-Up Study for Adults Previously Treated with Century Therapeutics Cellular Therapy

What this Trial Is About

This research aims to collect long-term safety and survival information from people who were treated previously with cellular therapy products in a Century Therapeutics-sponsored study. It focuses on monitoring any late side effects or risks that may arise after such treatments, especially those involving induced pluripotent stem cell iPSC-derived, genome-edited cellular therapies. The study helps understand long-term outcomes related to these advanced cellular treatments for hematological and solid tumor malignancies. Participants who received at least one dose of these cellular therapy products in earlier eligible Century trials will be followed for up to 180 months after their last treatment. This is an observational study with no new treatments given. During this time, researchers will track safety events, survival, and the persistence of the cellular product in the body. Throughout the study, participants will attend scheduled visits for safety monitoring, including checking for any special adverse events and serious side effects possibly related to the cellular therapy. Researchers will also observe overall survival and measure how long the cellular product remains in the participant. The study involves no intervention and continues until 180 months or death, whichever comes first.

A Study for Participants Previously Treated With Century Therapeutics Cellular Therapy Product